OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
Mads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 523-532
Open Access | Times Cited: 43
Mads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 523-532
Open Access | Times Cited: 43
Showing 26-50 of 43 citing articles:
Therapeutic potential of rifaximin in liver diseases
Wanting Yang, Gaoyue Guo, Chao Sun
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117283-117283
Open Access | Times Cited: 3
Wanting Yang, Gaoyue Guo, Chao Sun
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117283-117283
Open Access | Times Cited: 3
Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease
Mads Israelsen, Maria Camila Alvarez Silva, Bjørn Stæhr Madsen, et al.
Gut (2023) Vol. 73, Iss. 6, pp. 1041-1044
Closed Access | Times Cited: 7
Mads Israelsen, Maria Camila Alvarez Silva, Bjørn Stæhr Madsen, et al.
Gut (2023) Vol. 73, Iss. 6, pp. 1041-1044
Closed Access | Times Cited: 7
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Ellen Jensen, Mads Israelsen, Aleksander Krag
Hepatology Communications (2024) Vol. 8, Iss. 11
Open Access | Times Cited: 2
Ellen Jensen, Mads Israelsen, Aleksander Krag
Hepatology Communications (2024) Vol. 8, Iss. 11
Open Access | Times Cited: 2
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
Emil Deleuran Hansen, Nikolaj Torp, Stine Johansen, et al.
JHEP Reports (2024) Vol. 7, Iss. 1, pp. 101200-101200
Open Access | Times Cited: 2
Emil Deleuran Hansen, Nikolaj Torp, Stine Johansen, et al.
JHEP Reports (2024) Vol. 7, Iss. 1, pp. 101200-101200
Open Access | Times Cited: 2
Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
Aldo Torre, Jacqueline Córdova‐Gallardo, Alberto Munari
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 839-851
Open Access | Times Cited: 4
Aldo Torre, Jacqueline Córdova‐Gallardo, Alberto Munari
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 839-851
Open Access | Times Cited: 4
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review
Herbert L. DuPont
Clinical Microbiology Reviews (2023) Vol. 36, Iss. 4
Open Access | Times Cited: 4
Herbert L. DuPont
Clinical Microbiology Reviews (2023) Vol. 36, Iss. 4
Open Access | Times Cited: 4
Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
Guihua Fang, Shuna Liu, Bin Liu
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Guihua Fang, Shuna Liu, Bin Liu
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Research Priorities and Future Landscape of Clinical Trials in Alcohol-Associated Liver Disease
Anand V. Kulkarni, Ashwani K. Singal, Patrick S. Kamath
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 831-851
Closed Access | Times Cited: 1
Anand V. Kulkarni, Ashwani K. Singal, Patrick S. Kamath
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 831-851
Closed Access | Times Cited: 1
Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial
Xiao Quan Huang, Ying Jie Ai, Feng Li, et al.
Journal of Digestive Diseases (2024) Vol. 25, Iss. 8, pp. 504-516
Closed Access | Times Cited: 1
Xiao Quan Huang, Ying Jie Ai, Feng Li, et al.
Journal of Digestive Diseases (2024) Vol. 25, Iss. 8, pp. 504-516
Closed Access | Times Cited: 1
The steatotic liver disease burden paradox: unravelling the key role of alcohol
Nikolaj Torp, Mads Israelsen, Aleksander Krag
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Nikolaj Torp, Mads Israelsen, Aleksander Krag
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Rifaximin-α in alcohol-associated liver disease
Chencheng Xie, Ashwani K. Singal
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 495-497
Closed Access | Times Cited: 3
Chencheng Xie, Ashwani K. Singal
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 495-497
Closed Access | Times Cited: 3
Long non-coding RNAs: key regulators of liver and kidney fibrogenesis
Su-hyang Han, Je Yeong Ko, Eun Seo Kang, et al.
BMB Reports (2023) Vol. 56, Iss. 7, pp. 374-384
Open Access | Times Cited: 1
Su-hyang Han, Je Yeong Ko, Eun Seo Kang, et al.
BMB Reports (2023) Vol. 56, Iss. 7, pp. 374-384
Open Access | Times Cited: 1
Rifaximin-α: A Promising Ally in the Battle Against Alcohol-Related Liver Disease
Ashish Kumar, Anil Arora, Praveen Sharma
Journal of Clinical and Experimental Hepatology (2023) Vol. 14, Iss. 1, pp. 101218-101218
Open Access | Times Cited: 1
Ashish Kumar, Anil Arora, Praveen Sharma
Journal of Clinical and Experimental Hepatology (2023) Vol. 14, Iss. 1, pp. 101218-101218
Open Access | Times Cited: 1
The Application of Rifaximin in Patients with End Stage Liver Disease
皓月 田
Advances in Clinical Medicine (2024) Vol. 14, Iss. 01, pp. 466-475
Closed Access
皓月 田
Advances in Clinical Medicine (2024) Vol. 14, Iss. 01, pp. 466-475
Closed Access
H2S-driven Chemotherapy and Mild Photothermal Therapy Induced Mitochondrial Reprogramming to Promote Cuproptosis
Lihong Qiao, Yijing Ou, Lin Li, et al.
Research Square (Research Square) (2024)
Open Access
Lihong Qiao, Yijing Ou, Lin Li, et al.
Research Square (Research Square) (2024)
Open Access
Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis
Timothy R. Morgan
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 747-760
Closed Access
Timothy R. Morgan
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 747-760
Closed Access
Rifaximin-α for ALD: phase II results
Jordan Hindson
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 5, pp. 269-269
Closed Access
Jordan Hindson
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 5, pp. 269-269
Closed Access
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors’ reply
Mads Israelsen, Nikolaj Torp, Stine Johansen, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 604-604
Closed Access
Mads Israelsen, Nikolaj Torp, Stine Johansen, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 604-604
Closed Access
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease
Sweta Rose, Sunil Taneja, Ajay Duseja
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 603-604
Closed Access
Sweta Rose, Sunil Taneja, Ajay Duseja
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 603-604
Closed Access
